Advertisement
AZTR vs DARE
Which Stock Would AI Choose? Azitra (AZTR) vs. Daré Bioscience (DARE) Stock Comparison
Key Takeaways
- AZTR (Azitra) and DARE (Daré Bioscience) are both micro-cap, clinical-stage biotechnology companies, but they operate in different therapeutic niches: precision dermatology versus women's health.
- Both stocks have experienced substantial share-price volatility and dilution pressure in recent quarters, a common pattern among early-stage biotechs funding research through equity raises.
- AZTR is pivoting toward a near-term cosmetics and cosmeceuticals opportunity while continuing its dermatology drug programs, whereas DARE has a commercialized product plus two Phase 3 candidates.
- Relative performance and market positioning diverge on catalysts: DARE leans on clinical and regulatory milestones, while AZTR is more sensitive to financing and listing-compliance developments.
- For deeper context on each company, readers can review AZTR Major News and AZTR Today's Price Move, as well as DARE Major News and DARE Today's Price Move.
- Traders seeking data-driven signals can explore Trending AI Robots to see which algorithmic strategies are currently favored across the market.
Introduction
This stock comparison examines two small-cap biotechnology names that often attract traders looking for high-risk, high-reward exposure: AZTR and DARE. Although both trade at low per-share prices and share the financing challenges typical of pre-profit biotechs, their underlying businesses, pipelines, and catalysts are fundamentally different. Investors weighing relative performance and market positioning between a dermatology-focused developer and a women's health specialist may find this comparison useful. The analysis focuses on recent market activity, business fundamentals, and observable catalysts rather than short-term price noise.
AZTR Overview and Recent Performance
AZTR, or Azitra, Inc., is a clinical-stage biopharmaceutical company headquartered in Branford, Connecticut, focused on precision dermatology. The company develops engineered proteins and topical live biotherapeutic products targeting skin conditions, with lead programs including ATR-12 for Netherton syndrome, ATR-04 for rash associated with epidermal growth factor receptor (EGFR) inhibitor therapy, and ATR-01 for ichthyosis vulgaris.
In recent weeks, AZTR has drawn attention for its pivot toward the consumer cosmetics and cosmeceuticals market using its filaggrin protein and peptide technology, a move management frames as a near-term path to commercialization. The company has raised capital through private placements and warrant structures to fund these initiatives. At the same time, it has contended with a continued listing standard notice from the NYSE American exchange related to stockholders' equity levels, adding to the stock's volatility. Reverse stock splits in prior periods and elevated share turnover have amplified percentage swings, making sentiment highly reactive to financing and operational headlines.
DARE Overview and Recent Performance
DARE, or Daré Bioscience, Inc., is a women's health biotech based in San Diego, California, developing therapies across contraception, fertility, vaginal and sexual health, and menopause. Its portfolio includes XACIATO, an approved single-dose antibacterial gel for bacterial vaginosis, as well as two late-stage candidates: Ovaprene, a hormone-free monthly contraceptive in Phase 3 development, and Sildenafil Cream for female sexual arousal disorder, also in Phase 3.
Recent market activity in DARE has reflected the ongoing challenge of funding a broad pipeline while generating limited commercial revenue. The company reported revenue growth tied to its commercial product in recent quarters but continues to operate at a net loss. Like its peer, DARE has relied on equity and warrant-based financing, which can pressure the share price. Positive clinical or regulatory milestones, particularly around Ovaprene, have historically served as catalysts, while slower-than-expected commercialization has weighed on sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading bots drawn from a broader library of hundreds of automated strategies that collectively trade thousands of different tickers. Because market conditions change constantly, only the best-performing and most suitable bots earn a place in this featured section. Each bot has its own trading style, strategy, timeframe, performance statistics, and set of tickers it monitors, giving traders a range of approaches to evaluate. Exploring the page can help investors understand how systematic, data-driven strategies are currently positioned across the market. Visit Trending AI Robots to review the latest selections.
Head-to-Head Comparison
The clearest contrast between AZTR and DARE lies in business maturity and focus. DARE operates a single women's health segment, has an FDA-approved product on the market, and runs two Phase 3 programs, providing multiple potential catalysts. AZTR, by comparison, is earlier in its clinical timeline and is supplementing its drug pipeline with a consumer-facing cosmetics strategy to accelerate value creation.
From a risk standpoint, both companies carry elevated dilution and financing risk, and both trade well below prior highs. However, AZTR faces an additional structural overhang in the form of its exchange listing compliance timeline, which can intensify volatility around any capital or equity news. DARE's risk is more concentrated in clinical execution and the pace of commercial adoption. In terms of momentum, both names have shown weak relative performance in recent weeks, though their drivers differ: AZTR is financing-driven, while DARE is milestone-driven.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and the clarity of upcoming catalysts, Tickeron's AI would likely assign a modest relative edge to DARE. The company's approved product and multiple late-stage clinical programs provide a more defined pipeline of potential catalysts, while AZTR's profile is currently more exposed to financing and listing-compliance uncertainty. That said, neither name displays strong trend stability at present, and the AI's assessment remains probabilistic rather than definitive. Traders should treat any single-stock signal with caution given the high volatility common to micro-cap biotechs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTR is a Hold and DARE is a Hold.
AZTR's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for AZTR moved out of overbought territory on October 27, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 instances where the indicator moved out of the overbought zone. In 9 of the 9 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZTR as a result. In 54 of 56 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AZTR turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 29 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
AZTR moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AZTR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +14.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTR advanced for three days, in 119 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
AZTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.053) is normal, around the industry mean (3.498). P/E Ratio (36.625) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (146.534) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. AZTR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
DARE's RSI Indicator ascends from oversold territory
The RSI Oscillator for DARE moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In 31 of the 38 cases the stock moved higher. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 63 cases where DARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on DARE as a result. In 72 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for DARE just turned positive on October 30, 2026. Looking at past instances where DARE's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
Following a +2.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where DARE advanced for three days, in 165 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for DARE entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-22.504) is normal, around the industry mean (3.498). P/E Ratio (-0.972) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.502) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. DARE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
DARE | ||
|---|---|---|
OUTLOOK RATING 1..100 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 87 | |
P/E GROWTH RATING 1..100 | 9 | |
SEASONALITY SCORE 1..100 | 9 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AZTR | DARE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| Advances ODDS (%) | 9 days ago 81% | 1 day ago 75% |
| Declines ODDS (%) | 1 day ago 90% | 9 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 90% | N/A |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 77% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTR’s FA Score shows that 1 FA rating(s) are green while DARE’s FA Score has 2 green FA rating(s).
- AZTR’s FA Score: 1 green, 4 red.
- DARE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTR’s TA Score shows that 3 TA indicator(s) are bullish while DARE’s TA Score has 5 bullish TA indicator(s).
- AZTR’s TA Score: 3 bullish, 6 bearish.
- DARE’s TA Score: 5 bullish, 2 bearish.
Price Growth
AZTR (@Biotechnology) experienced а -32.11% price change this week, while DARE (@Biotechnology) price change was +6.48% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
AZTR is expected to report earnings on Nov 11, 2026.
DARE is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AZTR and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTR has been closely correlated with DARE. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if AZTR jumps, then DARE could also see price increases.
| Ticker / NAME | Correlation To AZTR | 1D Price Change % | ||
|---|---|---|---|---|
| AZTR | 100% | -2.47% | ||
| DARE - AZTR | 73% Closely correlated | +0.29% | ||
| PHIO - AZTR | 34% Loosely correlated | -0.07% | ||
| EYPT - AZTR | 32% Poorly correlated | -11.75% | ||
| GUTS - AZTR | 28% Poorly correlated | +8.70% | ||
| DYAI - AZTR | 28% Poorly correlated | +6.01% | ||
More | ||||
DARE and
Correlation & Price change
A.I.dvisor indicates that over the last year, DARE has been closely correlated with AZTR. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DARE jumps, then AZTR could also see price increases.
| Ticker / NAME | Correlation To DARE | 1D Price Change % | ||
|---|---|---|---|---|
| DARE | 100% | +0.29% | ||
| AZTR - DARE | 73% Closely correlated | -2.47% | ||
| CYTK - DARE | 42% Loosely correlated | +4.18% | ||
| AXON - DARE | 39% Loosely correlated | +4.26% | ||
| AMRN - DARE | 34% Loosely correlated | -0.34% | ||
| SNTI - DARE | 32% Poorly correlated | +11.81% | ||
More | ||||